- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06882941
Modulation of the Gut Microbiota and Metabolism in Elderly by Algae Products.
The goal of this clinical trial is to determine whether a fermented black soybean and adlay supplement can improve frailty. The main questions it seeks to answer are:
- Does the fermented black soybean and adlay supplement improve physical performance?
- What is the effect of the fermented black soybean and adlay supplement on gut microbiota? Researchers will compare the fermented black soybean and adlay supplement to a placebo (a non-fermented black soybean and adlay supplement) to assess its impact on physical performance.
Participants will:
- Take either the fermented black soybean and adlay supplement or a placebo daily for 12 weeks.
- Visit the clinic for checkups and tests before and after consuming the product.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan
- National Taiwan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 65 years or older
- Independent in activities of daily living
Exclusion Criteria:
- Being bedridden or residing in a nursing home
- Having a life expectancy of less than 6 months
- Having severe hearing or communication disorders
- Having hyperuricemia, gouty arthritis, or swallowing dysfunction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Non-Fermented Black Soybean and Adlay Supplement
The placebo product was prepared using uninoculated autoclaved black soybean and dehulled adlay.
The samples were provided as frozen food and required microwaving for 30 seconds before serving.
Participants assigned to the placebo group will take the non-fermented black soybean and adlay supplement daily for 12 weeks.
|
The placebo product was prepared using uninoculated autoclaved black soybean and dehulled adlay.
The samples were provided as frozen food and required microwaving for 30 seconds before serving.
Participants assigned to the placebo group will take the non-fermented black soybean and adlay supplement daily for 12 weeks.
|
|
Experimental: Fermented Black Soybean and Adlay Supplement
The preparation of the fermented black soybean and adlay supplement involves autoclaved black soybean and dehulled adlay, which are inoculated with Bacillus subtilis natto (1.3 × 10⁶ CFU/g) and incubated for 43 hours at 28°C.
Participants assigned to the experimental group will take the Fermented Black Soybean and Adlay Supplement daily for 12 weeks.
|
The preparation of the fermented black soybean and adlay supplement involves autoclaved black soybean and dehulled adlay, which are inoculated with Bacillus subtilis natto (1.3 × 10⁶ CFU/g) and incubated for 43 hours at 28°C.
Participants assigned to the experimental group will take the Fermented Black Soybean and Adlay Supplement daily for 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
frailty status
Time Frame: From enrollment to the end of treatment at 12 weeks
|
Frailty status will be assessed using modified Fried's criteria before and after consuming the product.
|
From enrollment to the end of treatment at 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
gut microbiota
Time Frame: From enrollment to the end of treatment at 12 weeks
|
Gut microbiota will be analyzed via fecal sample collection before and after consuming the product.
|
From enrollment to the end of treatment at 12 weeks
|
|
Physical performance: 5-meter walk speed
Time Frame: From enrollment to the end of treatment at 12 weeks
|
5-meter walk speed will be evaluated before and after consuming the product.
The participant will be asked to walk at their normal comfortable pace until they reach the end of the 5-meter mark.
|
From enrollment to the end of treatment at 12 weeks
|
|
physical performance: Timed Up and Go test
Time Frame: From enrollment to the end of treatment at 12 weeks
|
Timed Up and Go test will be evaluated before and after consuming the product.
The Timed Up and Go test measures functional mobility by timing a participant as they rise from a chair, walk 3 meters, turn around, walk back, and sit down.
|
From enrollment to the end of treatment at 12 weeks
|
|
physical performance: 30-second chair stand test
Time Frame: From enrollment to the end of treatment at 12 weeks
|
Thirty-second chair stand test will be evaluated before and after consuming the product. The 30-Second Chair Stand Test measures lower body strength and endurance by counting the number of times a participant can fully stand up from a chair and sit back down within 30 seconds. |
From enrollment to the end of treatment at 12 weeks
|
|
physical performance: grip strength
Time Frame: From enrollment to the end of treatment at 12 weeks
|
Grip strength will be measured before and after consuming the product.
Grip strength measurement assesses upper body muscle strength by using a dynamometer to measure the maximum force exerted when a participant squeezes the device with their dominant hand.
|
From enrollment to the end of treatment at 12 weeks
|
|
Number of participants with biochemistry blood tests.
Time Frame: From enrollment to the end of treatment at 12 weeks
|
Biochemical data from blood samples of the 141 participants will be analyzed before and after consuming the product.
|
From enrollment to the end of treatment at 12 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201804003RINB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.